For example, we observed that treating cultures of MDA-MB-231 breast carcinoma cells (which have a gain-of-function p53 mutation and which contain a subpopulation of giant cells even prior to drug exposure [89]), with moderate (i.e., CF-assay range) concentrations of cisplatin (≤ 10 μM for 72 h) again primarily triggered a cytostatic rather than cytotoxic response, with > 50% of the cells exhibiting prominent PGCC characteristics [72]. Here, TP53 is linked to breast carcinoma.